Sex-specific aspects of venous thrombosis

Leiden Repository

Sex-specific aspects of venous thrombosis

Type: Doctoral Thesis
Title: Sex-specific aspects of venous thrombosis
Author: Roach, Rachel Elizabeth Jo
Publisher: Department of Clinical Epidemiology, Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University
Issue Date: 2014-02-06
Keywords: Venous thrombosis
Epidemiology
Risk factors
Sex
Oral contraception
Postmenopausal hormone therapy
Pregnancy
Recurrent venous thrombosis
Abstract: Venous thrombosis is a disease that occurs in 1-2 per 1000 people per year. At the time of their first venous thrombosis, approximately 50% of women are exposed to reproductive risk factors (oral contraception, postmenopausal hormone therapy, pregnancy and the puerperium). In this thesis, we showed that these women are at particularly high risk of venous thrombosis if they have previously experienced an episode of superficial vein thrombosis, or are over the age of 50 years (Chapters 2 and 3). There is no known male counterpart to female reproductive risk factors. Nevertheless, the incidence of venous thrombosis is approximately similar in men and women. In this thesis we established that, once female reproductive risk factors are taken into account, men have an approximately twofold higher risk of both first and recurrent venous thrombosis than women (Chapters 4 and 5). Further to these findings, in Chapter 6, we reviewed the literature on sex-specific risk factors for venous thrombosis. We hypothesized that sex-specific genetic risk factors, an excess in overweight and smoking, or hypercoagulable changes such as microalbuminuria may explain the higher risk of venous thrombosis in men than in women.
Description: Promotor: F.R. Rosendaal, Co-Promotores: W.M. Lijfering, S.C. Cannegieter
With Summary in Dutch
Faculty: LUMC
Citation: Roach, R.E.J., 2014, Doctoral Thesis, Leiden University
ISBN: 9789090279091
Sponsor: Part of the research described in this thesis was supported by the Dutch Heart Foundation (DHS 98.113), the Dutch Cancer Foundation (RUL 99/1992) and the Netherlands Organization for Scientific Research (912-03-033| 2003). Financial support by the Dutch Heart Foundation and the Federatie van Nederlandse Trombosediensten for the publication of this thesis is gratefully acknowledged. Additional financial support was kindly provided by Medical Dynamics, ABN Amro, Boehringer Ingelheim, GlaxoSmithKline, LeoPharma BV and Bayer HealthCare.
Handle: http://hdl.handle.net/1887/23449
 

Files in this item

Description Size View
application/pdf Full Text 3.657Mb Under embargo
application/pdf Cover 2.572Mb Under embargo
application/pdf Title Pages_Contents 204.2Kb Under embargo
application/pdf Chapter 1 356.3Kb Under embargo
application/pdf Chapter 2 400.9Kb Under embargo Full text at publisher site
application/pdf Chapter 3 359.8Kb Under embargo Full text at publisher site
application/pdf Chapter 4 411.3Kb Under embargo Full text at publisher site
application/pdf Chapter 5 432.3Kb Under embargo
application/pdf Chapter 6 400.9Kb Under embargo
application/pdf Chapter 7 307.9Kb Under embargo
application/pdf Summary in Dutch 278.3Kb Under embargo
application/pdf Acknowledgements_Publications_Curriculum Vitae 243.5Kb Under embargo
application/pdf Propositions 559.8Kb Under embargo

This item appears in the following Collection(s)